| Crohn Disease
Renflexis vs Tysabri
Side-by-side clinical, coverage, and cost comparison for crohn disease.Deep comparison between: Renflexis vs Tysabri with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTysabri has a higher rate of injection site reactions vs Renflexis based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Tysabri but not Renflexis, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Renflexis
Tysabri
At A Glance
IV infusion
Every 6-8 weeks
TNF-alpha antagonist
IV infusion
Every 4 weeks
alpha4-integrin antagonist
Indications
- Crohn Disease
- Ulcerative Colitis
- Rheumatoid Arthritis
- Ankylosing spondylitis
- Arthritis, Psoriatic
- Psoriasis vulgaris
- Multiple Sclerosis
- Crohn Disease
Dosing
Crohn Disease, Ulcerative Colitis, Arthritis, Psoriatic, Psoriasis vulgaris 5 mg/kg IV induction at 0, 2, and 6 weeks, then 5 mg/kg every 8 weeks; pediatric patients >= 6 years with Crohn Disease or Ulcerative Colitis receive the same regimen.
Rheumatoid Arthritis 3 mg/kg IV induction at 0, 2, and 6 weeks, then 3 mg/kg every 8 weeks in combination with methotrexate; may increase up to 10 mg/kg every 8 weeks or every 4 weeks for incomplete response.
Ankylosing spondylitis 5 mg/kg IV induction at 0, 2, and 6 weeks, then 5 mg/kg every 6 weeks.
Multiple Sclerosis 300 mg IV infusion over one hour every four weeks.
Crohn Disease 300 mg IV infusion over one hour every four weeks; discontinue if no therapeutic benefit by 12 weeks of induction therapy or if concomitant corticosteroids cannot be tapered within six months of starting therapy.
Contraindications
- Doses >5 mg/kg in patients with moderate or severe heart failure
- Previous severe hypersensitivity reaction to infliximab products, any inactive ingredient of RENFLEXIS, or any murine proteins
- Progressive multifocal leukoencephalopathy (PML), current or historical
- Previous hypersensitivity reaction to TYSABRI, ranging from urticaria to anaphylaxis
Adverse Reactions
Most common (>10%) Infections (upper respiratory, sinusitis, pharyngitis), infusion-related reactions, headache, abdominal pain
Serious Serious infections (pneumonia, cellulitis, abscess, sepsis, tuberculosis), hepatotoxicity, malignancies, severe infusion reactions
Postmarketing Neutropenia, agranulocytosis, interstitial lung disease, Stevens-Johnson Syndrome, toxic epidermal necrolysis, acute liver failure, anaphylactic shock, cerebrovascular accidents, myocardial ischemia/infarction
Most common (>=10%) Headache, fatigue (MS and CD); arthralgia, urinary tract infection, lower respiratory tract infection, gastroenteritis, vaginitis, depression, pain in extremity, abdominal discomfort, diarrhea, rash (MS); upper respiratory tract infection, nausea (CD).
Serious Progressive multifocal leukoencephalopathy (PML), herpes infections, hepatotoxicity, hypersensitivity and antibody formation, immunosuppression and infections, hematological abnormalities.
Postmarketing Hemolytic anemia, thrombocytopenia (including immune thrombocytopenic purpura).
Pharmacology
TNF-alpha antagonist; infliximab-abda is a chimeric IgG1kappa monoclonal antibody that neutralizes TNF-alpha by binding with high affinity to soluble and transmembrane forms of TNF-alpha, inhibiting receptor binding and suppressing downstream pro-inflammatory activity.
Alpha4-integrin antagonist; recombinant humanized IgG4 monoclonal antibody that binds to the alpha4-subunit of alpha4beta1 and alpha4beta7 integrins on leukocytes, blocking their adhesion to VCAM-1 and MAdCAM-1 and inhibiting transmigration into inflamed parenchymal tissue in multiple sclerosis and Crohn's disease.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Renflexis
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (0/12)
Tysabri
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
UnitedHealthcare
Renflexis
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Tysabri
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Renflexis
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (0/3)
Tysabri
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Renflexis.
Cost estimate not availableAccessia Health: Multiple Sclerosis - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
RenflexisView full Renflexis profile
TysabriView full Tysabri profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.